Zydus has launched Vaxiflutm, a trivalent influenza vaccine, in India to provide protection against seasonal flu. The vaccine is designed to target three influenza virus strains and strengthen immunity against flu-related illnesses, particularly in vulnerable populations such as children, the elderly, and individuals with chronic health conditions. The launch reinforces Zydus’s commitment to preventive healthcare and supports India’s immunization efforts ahead of the flu season.

Key highlights

Vaccine details:

• Trivalent formulation targeting three flu virus strains.

• Suitable for adults and children at risk of seasonal influenza.

• Administered via intramuscular injection as per standard protocols.

Public health relevance:

• Reduces the risk of influenza-related complications, hospitalizations, and economic burden.

• Important for populations with chronic conditions like asthma, diabetes, and cardiovascular diseases.

• Helps mitigate flu outbreaks in community and healthcare settings.

Regulatory and market information:

• Fully approved for use in India under local regulatory guidelines.

• Adds to Zydus’s portfolio of vaccines, strengthening preventive care offerings.

  
  

The introduction of Vaxiflutm highlights the importance of preventive immunization against influenza, especially in high-risk populations. Pharmacists and healthcare providers play a critical role in recommending the vaccine to patients, ensuring timely administration, and helping reduce the burden of seasonal flu across India.